DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE

United Kingdom Research and Innovation (UKRI)

Status: Completed

Conditions: Kidney Cancer

Treatments: Other: laboratory biomarker analysis; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Genetic: polymorphism analysis; Genetic: mutation analysis

Study type: Observational

Funder types: Other

Identifiers

NCT00900536

CDR0000601175 (Registry Identifier)

EU-20867

ISRCTN38934710

MRC-RE05-TRANSORCE

EUDRACT-2006-006079-19

Details and patient eligibility

About

RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to sorafenib.

PURPOSE: This research study is looking at the DNA in blood and/or tissue samples from patients with primary kidney cancer receiving sorafenib on clinical trial MRC-RE05-SORCE.

Full description

OBJECTIVES:

• Examine the relationship between tumor genotype, expression, and patient outcome.
• Examine the relationship between constitutional genotype and patient outcome.

OUTLINE: This is a multicenter study.

Patients undergo blood and/or tissue sample collection for laboratory studies. Laboratory studies include generation of tissue microarrays; analysis of protein expression by immunohistochemistry; tumor DNA extraction and whole genome amplification; detection of VHL or other relevant gene mutations by direct sequencing; and constitutional (lymphocyte DNA) genotyping by single nucleotide polymorphism analysis.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed resected renal cell carcinoma

  • Clear cell or non-clear cell tumor

• Receiving sorafenib tosylate on clinical trial MRC-RE05-SORCE

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics